MAZE Overview

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Wall Street analysts forecast MAZE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MAZE is52.00 USD with a low forecast of 46.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Maze Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Maze Therapeutics Inc. EPS for the last quarter amounts to -0.66 USD, increased 1000.00

Maze Therapeutics Inc (MAZE) has 125 emplpoyees as of March 11 2026.

Today MAZE has the market capitalization of 2.46B USD.